Summary not available.
Summary not available.
Summary not available.
Protect Pharmaceutical Corp. (OTC: PRTT) has appointed Ali Yildiz as President and finalized the acquisition of Antarax Capital Danismanlik Limited, marking a significant move for the company. The completion of OTC filings allows the company to present enhanced financials to shareholders. In 2022, Protect Pharmaceutical reported revenues exceeding $90 million and anticipates modest growth in revenue and profitability for 2023. Yildiz expressed enthusiasm for advancing the company's goals with Antarax. The newly acquired Antarax specializes in logistics, providing air, sea, and land transportation services. Protect Pharmaceutical will also seek an auditor to conduct a full audit, promising to keep shareholders updated on progress.
Protect Pharmaceutical Corp. (PRTT) announces a significant change in control of its Preferred Series A shares and the appointment of Ali Yildiz as the new president. Yildiz, who has a proven track record in scaling companies, aims to enhance growth and stability. He is finalizing the acquisition of Antarax Capital Danismanlik Limited, a Turkish firm focused on logistics, which is anticipated to bring substantial shareholder value. This acquisition reflects the company's strategic moves to strengthen its position. Yildiz has expressed commitment to transparency with shareholders and will provide updates through OTC filings.
Protect Pharmaceutical Corporation (OTC:PRTT) has terminated its Share Exchange Agreement due to insufficient legal instruments for conducting transactions in Belarus, as announced on December 12, 2022. The agreement, signed on June 15, 2022, was not executed, with obligations remaining unfulfilled as of December 6, 2022, with no claims against either party. Financial statements for the second and third quarters of 2022 have been adjusted, reflecting the absence of new assets and liabilities. The company specializes in software development and related consulting services across various sectors.
Protect Pharmaceutical Corporation (OTC:PRTT) has acquired CJSC “Inaiapp”, a Belarusian company specializing in corporate software for business digitalization. Inaiapp brings 8 years of blockchain development experience and a solid client base to PRTT. The acquisition aims to enhance PRTT's capabilities in robotic process automation, AI, and machine learning, enabling the creation of more profitable solutions. Nick Greb, President of PRTT, emphasizes the strategic merger of US market presence with advanced technical expertise, aimed at accelerating business processes through innovation and security.
Protect Pharmaceutical Corporation (OTC: PRTT) has announced a share exchange agreement to acquire 100% of CJSC Inaiapp, a leading blockchain solutions provider in the EU. This strategic acquisition aims to enhance PRTT's position in the web 3.0 market and consolidate financial flows for its product development, including multiboxnft.com. Inaiapp brings eight years of blockchain experience and a strong management team, expected to significantly add value to PRTT's operations. The deal underscores PRTT's commitment to emerging tech innovation.
Protect Pharmaceutical Corporation, Inc. (OTC: PRTT) announced a merger with Aetsoft, a blockchain solutions provider, to acquire 100% of Aetsoft’s outstanding shares. This merger aims to enhance PRTT's position in the web 3.0 market and consolidate financial resources for upcoming product launches, including Multibox NFT. Aetsoft, established in 2014, brings significant blockchain development experience and advanced technology solutions, which are expected to add substantial value to PRTT and its shareholders.
Protect Pharmaceutical Corporation (OTC:PRTT) has announced the launch of its all-in-one e-commerce platform for NFTs, MultiBOXnft.com, aiming to capitalize on the growing NFT market projected to reach USD 147.24 billion by 2026. The platform will offer prebuilt design templates, an internal app store, and client support. The beta version is planned for release by the end of 2022, following a business analysis in early May.